JP5576591B2 - α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 - Google Patents
α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 Download PDFInfo
- Publication number
- JP5576591B2 JP5576591B2 JP2007500529A JP2007500529A JP5576591B2 JP 5576591 B2 JP5576591 B2 JP 5576591B2 JP 2007500529 A JP2007500529 A JP 2007500529A JP 2007500529 A JP2007500529 A JP 2007500529A JP 5576591 B2 JP5576591 B2 JP 5576591B2
- Authority
- JP
- Japan
- Prior art keywords
- day
- cancer
- ftd
- administration
- trifluorothymidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007500529A JP5576591B2 (ja) | 2005-01-26 | 2006-01-25 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| US11/042,059 | 2005-01-26 | ||
| JP2005165156 | 2005-06-06 | ||
| JP2005165156 | 2005-06-06 | ||
| JP2007500529A JP5576591B2 (ja) | 2005-01-26 | 2006-01-25 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2006080327A1 JPWO2006080327A1 (ja) | 2008-06-19 |
| JP5576591B2 true JP5576591B2 (ja) | 2014-08-20 |
Family
ID=36740357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500529A Expired - Lifetime JP5576591B2 (ja) | 2005-01-26 | 2006-01-25 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1849470B2 (show.php) |
| JP (1) | JP5576591B2 (show.php) |
| KR (1) | KR101468216B1 (show.php) |
| AU (1) | AU2006209547C1 (show.php) |
| BE (1) | BE2017C028I2 (show.php) |
| CA (1) | CA2594713A1 (show.php) |
| CY (2) | CY1119393T1 (show.php) |
| DK (1) | DK1849470T4 (show.php) |
| ES (1) | ES2630002T5 (show.php) |
| FI (1) | FI1849470T4 (show.php) |
| FR (1) | FR17C1028I2 (show.php) |
| HU (2) | HUE033306T2 (show.php) |
| LT (2) | LT1849470T (show.php) |
| LU (1) | LUC00036I2 (show.php) |
| NL (1) | NL300889I2 (show.php) |
| PL (1) | PL1849470T5 (show.php) |
| PT (1) | PT1849470T (show.php) |
| RU (1) | RU2394581C2 (show.php) |
| SI (1) | SI1849470T2 (show.php) |
| TW (1) | TWI362265B (show.php) |
| WO (1) | WO2006080327A1 (show.php) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| JP5576591B2 (ja) | 2005-01-26 | 2014-08-20 | 大鵬薬品工業株式会社 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| WO2008132443A1 (en) | 2007-04-25 | 2008-11-06 | Cyclacel Limited | Use of sapacitabine to treat proliferative disease |
| JP5774853B2 (ja) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 医薬投薬形 |
| DK2273983T3 (en) | 2008-05-09 | 2016-09-19 | Gruenenthal Gmbh | A process for the preparation of a powdery formulation intermediate and a fixed final dosage form using a sprøjtestørkningstrin |
| EP2303283A2 (en) * | 2008-05-15 | 2011-04-06 | Katholieke Universiteit Leuven K.U. Leuven R&D | Anti-cancer combination therapy |
| TW201105316A (en) | 2009-07-22 | 2011-02-16 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| RU2015138422A (ru) | 2009-07-22 | 2018-12-25 | Грюненталь Гмбх | Стабильная при окислении, прочная на излом лекарственная форма |
| MX2013002293A (es) | 2010-09-02 | 2013-05-09 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico. |
| JP5925779B2 (ja) | 2010-09-02 | 2016-05-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 無機塩を含む不正使用抵抗性剤形 |
| WO2013017242A1 (en) | 2011-07-29 | 2013-02-07 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| CN103841964A (zh) | 2011-07-29 | 2014-06-04 | 格吕伦塔尔有限公司 | 提供药物立即释放的抗破碎片剂 |
| PL2746404T3 (pl) | 2011-08-16 | 2018-04-30 | Taiho Pharmaceutical Co., Ltd. | Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| TWI503122B (zh) | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| JP6117249B2 (ja) | 2012-02-28 | 2017-04-19 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形 |
| AU2013233226B2 (en) | 2012-03-14 | 2016-05-19 | Nisshin Pharma Inc. | Sulfur amino acid-containing composition |
| WO2013156453A1 (en) | 2012-04-18 | 2013-10-24 | Grünenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| JP6381523B2 (ja) | 2012-05-16 | 2018-08-29 | ノバルティス アーゲー | Ｐｉ−３キナーゼ阻害剤の投与レジメン |
| RU2668125C2 (ru) * | 2013-03-27 | 2018-09-26 | Тайхо Фармасьютикал Ко., Лтд. | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат |
| ES2824400T3 (es) * | 2013-03-27 | 2021-05-12 | Taiho Pharmaceutical Co Ltd | Agente antitumoral que incluye clorhidrato de irinotecán hidratado |
| WO2014185528A1 (ja) * | 2013-05-17 | 2014-11-20 | 大鵬薬品工業株式会社 | Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法 |
| BR112015026549A2 (pt) | 2013-05-29 | 2017-07-25 | Gruenenthal Gmbh | forma de dosagem à prova de violação contendo uma ou mais partículas |
| MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
| CA2917136C (en) | 2013-07-12 | 2022-05-31 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| DK3042669T3 (da) | 2013-09-06 | 2023-06-12 | Taiho Pharmaceutical Co Ltd | Antitumormiddel og forstærker af antitumorvirkning |
| CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
| US20150320690A1 (en) | 2014-05-12 | 2015-11-12 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| MX2017013637A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes. |
| EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| AU2017205531B2 (en) | 2016-01-08 | 2021-05-13 | Les Laboratoires Servier | Anti-tumor agent containing immunomodulator and anti-tumor effect potentiator |
| EP3412295A4 (en) * | 2016-02-05 | 2019-09-25 | Taiho Pharmaceutical Co., Ltd. | METHOD FOR THE TREATMENT OF CANCER PATIENTS WITH HEAVY NIER FUNCTION TROUBLESHOOTING |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| WO2019124544A1 (ja) | 2017-12-22 | 2019-06-27 | 大鵬薬品工業株式会社 | トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法 |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744475A (en) | 1995-03-29 | 1998-04-28 | Taiho Pharmaceutical Co., Ltd. | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
| WO1998013045A1 (en) * | 1996-09-24 | 1998-04-02 | Taiho Pharmaceutical Co., Ltd. | Cancerous metastasis inhibitors containing uracil derivatives |
| JP5576591B2 (ja) | 2005-01-26 | 2014-08-20 | 大鵬薬品工業株式会社 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
-
2006
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja not_active Expired - Lifetime
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en active Active
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 RU RU2007132181/15A patent/RU2394581C2/ru active
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es not_active Expired - Lifetime
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en not_active Expired - Lifetime
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko not_active Expired - Lifetime
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-07 CY CY2017029C patent/CY2017029I2/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Non-Patent Citations (3)
| Title |
|---|
| JPN6011054216; ＥＭＵＲＡ， Ｔ． ｅｔ ａｌ．: ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＭＯＬＥＣＵＬＡＲ ＭＥＤＩＣＩＮＥ Ｖｏｌ．１３， Ｎｏ．２, 2004, ｐ．２４９-２５５ * |
| JPN6011054217; ＢＡＹＥＳ， Ｍ． ｅｔ ａｌ．: Ｍｅｔｈｏｄｓ Ｆｉｎｄ Ｅｘｐ Ｃｌｉｎ Ｐｈａｒｍａｃｏｌ Ｖｏｌ．２６， Ｎｏ．１, 2004, ｐ．５３-８４ * |
| JPN6012005376; 江村智博 他: 第６３回日本癌学会学術総会予稿集 , 2004, ｐ．４６６ * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5576591B2 (ja) | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 | |
| USRE46284E1 (en) | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor | |
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| EP2036903B1 (en) | Potentiator of radiation therapy | |
| US20090281105A1 (en) | Radiotherapy enhancer | |
| EP2268287B1 (en) | Dosage regimens of an antitumor agent comprising deoxycytidine derivative | |
| TWI401085B (zh) | Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents | |
| HK1115306A (en) | ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR | |
| WO2022014025A1 (ja) | 血液がんの新規治療法及び新規治療剤 | |
| JPWO2012105486A1 (ja) | １日１回隔日投与を特徴とするテガフール含有組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081002 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111018 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111208 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120426 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20120426 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120510 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20120515 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120622 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20120626 |
|
| C141 | Inquiry by the administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C141 Effective date: 20131217 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20131217 |
|
| C54 | Written response to inquiry |
Free format text: JAPANESE INTERMEDIATE CODE: C54 Effective date: 20140217 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20140430 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20140430 |
|
| C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20140430 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140514 |
|
| C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20140701 |
|
| C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20140701 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140704 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5576591 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |